ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,26%
Bitcoin
66.958,58
2,64%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) News

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RNA
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202400h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
17/05/202400h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202415h10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
15/05/202415h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
15/05/202415h00PR Newswire (US)Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsNASDAQ:RNAAvidity Biosciences Inc
09/05/202422h22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
09/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/05/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
09/05/202422h05PR Newswire (US)Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
08/05/202422h05PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
08/05/202412h00PR Newswire (US)Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1NASDAQ:RNAAvidity Biosciences Inc
08/05/202403h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
22/04/202422h05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
27/03/202414h00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
21/03/202421h05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
08/03/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
05/03/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
04/03/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
04/03/202413h00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialNASDAQ:RNAAvidity Biosciences Inc
01/03/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
29/02/202422h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
29/02/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
29/02/202418h00PR Newswire (US)Avidity Biosciences Honors Rare Disease Day®NASDAQ:RNAAvidity Biosciences Inc
29/02/202413h00PR Newswire (US)Avidity Biosciences Announces Oversubscribed $400 Million Private PlacementNASDAQ:RNAAvidity Biosciences Inc
28/02/202423h32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
28/02/202422h17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RNAAvidity Biosciences Inc
28/02/202422h05PR Newswire (US)Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
27/02/202415h00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
21/02/202422h05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
20/02/202415h00PR Newswire (US)Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 SkippingNASDAQ:RNAAvidity Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:RNA

Kürzlich von Ihnen besucht

NYSE
RBAC.WS
RedBall Acquisition
ASX
NXE
New Energy Minerals
USOTC
LOGL
Legend Oil and Gas (CE)
LSE
88HV
Westp. Sec 28
COIN
FRAZEUR
LSE
BA60
07jun2027c
LSE
MNDI
Mondi
CSE
GFI.DB.B
Gravitas Financial
GATE
NOAUSDT
NOA
NYSE
GBUY
Goldman Sachs ET
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten